Duration of Device-Based Fever Prevention after Cardiac Arrest

Christian Hassager, Henrik Schmidt, Jacob E Møller, Johannes Grand, Simon Mølstrøm, Rasmus P Beske, Søren Boesgaard, Britt Borregaard, Ditte Bekker-Jensen, Jordi S Dahl, Martin S Frydland, Dan E Høfsten, Yusuf A Isse, Jakob Josiassen, Vibeke R Lind Jørgensen, Daniel Kondziella, Matias G Lindholm, Emil Moser, Benjamin C Nyholm, Laust E R OblingLaura Sarkisian, Frederik T Søndergaard, Jakob H Thomsen, Jens J Thune, Søren Venø, Sebastian C Wiberg, Matilde Winther-Jensen, Martin A S Meyer, Jesper Kjaergaard

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

39 Downloads (Pure)

Abstract

BACKGROUND: Guidelines recommend active fever prevention for 72 hours after cardiac arrest. Data from randomized clinical trials of this intervention have been lacking.

METHODS: We randomly assigned comatose patients who had been resuscitated after an out-of-hospital cardiac arrest of presumed cardiac cause to device-based temperature control targeting 36°C for 24 hours followed by targeting of 37°C for either 12 or 48 hours (for total intervention times of 36 and 72 hours, respectively) or until the patient regained consciousness. The primary outcome was a composite of death from any cause or hospital discharge with a Cerebral Performance Category of 3 or 4 (range, 1 to 5, with higher scores indicating more severe disability; a category of 3 or 4 indicates severe cerebral disability or coma) within 90 days after randomization. Secondary outcomes included death from any cause and the Montreal Cognitive Assessment score (range, 0 to 30, with higher scores indicating better cognitive ability) at 3 months.

RESULTS: A total of 393 patients were randomly assigned to temperature control for 36 hours, and 396 patients were assigned to temperature control for 72 hours. At 90 days after randomization, a primary end-point event had occurred in 127 of 393 patients (32.3%) in the 36-hour group and in 133 of 396 patients (33.6%) in the 72-hour group (hazard ratio, 0.99; 95% confidence interval, 0.77 to 1.26; P = 0.70) and mortality was 29.5% in the 36-hour group and 30.3% in the 72-hour group. At 3 months, the median Montreal Cognitive Assessment score was 26 (interquartile range, 24 to 29) and 27 (interquartile range, 24 to 28), respectively. There was no significant between-group difference in the incidence of adverse events.

CONCLUSIONS: Active device-based fever prevention for 36 or 72 hours after cardiac arrest did not result in significantly different percentages of patients dying or having severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, NCT03141099.).

OriginalsprogEngelsk
TidsskriftThe New England Journal of Medicine
Vol/bind388
Udgave nummer10
Sider (fra-til)888-897
ISSN0028-4793
DOI
StatusUdgivet - 9. mar. 2023

Bibliografisk note

Copyright © 2022 Massachusetts Medical Society.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Duration of Device-Based Fever Prevention after Cardiac Arrest'. Sammen danner de et unikt fingeraftryk.

Citationsformater